Lucid Diagnostics Announces Pricing of Initial Public Offering
13. Oktober 2021 22:15 ET
|
Lucid Diagnostics Inc.
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:...
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
07. Oktober 2021 11:41 ET
|
PAVmed Inc.
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today...
Tim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors
14. Juni 2021 09:30 ET
|
PAVmed Inc.
NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today...
PAVmed Launches Digital Health Company Veris Health Inc.
02. Juni 2021 09:30 ET
|
PAVmed Inc.
New subsidiary Veris acquires privately held oncology digital health company Oncodisc Inc. Technologies include first intelligent implantable vascular access port with biologic sensors and...
PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck® Esophageal Cell Collection Device
26. Mai 2021 09:30 ET
|
PAVmed Inc.
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary...
PAVmed Receives European CE Mark Certification for its CarpX® Minimally Invasive Carpal Tunnel Device
25. Mai 2021 09:30 ET
|
PAVmed Inc.
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies
24. Mai 2021 09:30 ET
|
PAVmed Inc.
Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard capable of detecting esophageal precancer in chronic heartburn patients NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) --...
PAVmed Provides Business Update and First Quarter 2021 Financial Results
17. Mai 2021 16:00 ET
|
PAVmed Inc.
Conference call to be held today at 4:30 PM EDT NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product,...
PAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021
13. Mai 2021 09:30 ET
|
PAVmed Inc.
Dr. David Poppers to present on his initial experience with Lucid’s EsoCheck and EsoGuard NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”),...
PAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team
06. Mai 2021 09:30 ET
|
PAVmed Inc.
Four new senior executives will support growth strategy focused on multi-channel EsoGuard commercialization NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ)...